Patients on anifrolumab spent more time in remission and low disease activity, and reached those states more quickly, vs. placebo. Achieving these states can stave off permanent organ damage.

L.E.K. Consulting is a global strategy consultancy working with business leaders to seize competitive advantage and amplify growth. The insights are catalysts that reshape the trajectory of ...